Bank of Japan Signals Further Interest Rate Hikes as Inflation Trends Toward 2% Target 
Gold Prices Surge for Fourth Day as Middle East Tensions and Strong U.S. Dollar Shape Market 
Rachel Reeves Signals Fiscal Discipline in UK Budget Update Amid Middle East Tensions 
RBA Signals Possible March Rate Hike as Energy Risks Threaten Inflation Outlook 
Global Markets React as Dollar Surges, Swiss Franc Rallies After U.S.-Israel Strike on Iran 
Australia’s Economy Accelerates in Q4 2025 as Household Spending and Government Investment Rise 
European Stocks Slide as Middle East War Fears and Rising Oil Prices Shake Markets 
Asian Currencies Slide as US-Israel Strikes on Iran Trigger Oil Surge and Risk-Off Rally 
U.S.-Israel War on Iran Escalates as Gulf Conflict Disrupts Oil, Air Travel and Regional Security 
KOSPI Plunges Over 8% as U.S.-Iran War Sparks Global Risk Aversion and Profit-Taking 
Wall Street Futures Tumble as U.S.-Iran Conflict Escalates and Oil Prices Surge 
China Factory Activity Surges to Five-Year High as Demand Boosts Manufacturing PMI 
Gold Prices Rebound in Asia as U.S.–Iran Tensions Support Safe-Haven Demand 
Japan Manufacturing PMI Jumps to Four-Year High as Global Demand Strengthens 
Asian Markets Slide as Middle East Conflict Sparks Oil Price Surge and Inflation Fears 
South Korea Manufacturing PMI Rises for Third Month on Strong Semiconductor Demand 
Wall Street Closes Mixed as Tech Stocks Rally Despite U.S.–Iran Escalation and Oil Price Surge 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
